XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Oct. 31, 2017
Oct. 31, 2016
Operating activities    
Net (loss) income $ (1,797) $ 22,294
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:    
Depreciation and amortization 5,673 5,299
Deferred income taxes 1,317 (14,483)
Provision for doubtful accounts receivable 566 260
Realized gain on marketable securities (7)
Interest in the equity of investments 104 (263)
Stock-based compensation 810 702
Change in assets and liabilities:    
Restricted cash and cash equivalents 14,742 9,939
Trade accounts receivable (13,952) (13,132)
Prepaid expenses, other current assets and other assets (12,832) (10)
Trade accounts payable, accrued expenses, other current liabilities and other liabilities (9,359) 6,125
Customer deposits (14,226) (9,127)
Deferred revenue (1,556) (2,114)
Net cash (used in) provided by operating activities (30,517) 5,490
Investing activities    
Capital expenditures (5,324) (5,515)
Proceeds from sale of interest in Straight Path IP Group Holding, Inc. 6,000
Purchase of IP Interest from Straight Path Communications Inc. (6,000)
Cash used for investments (8,008)
Proceeds from sale and redemption of investments 2
Purchases of marketable securities (15,671) (10,969)
Proceeds from maturities and sales of marketable securities 19,560 6,001
Net cash used in investing activities (1,435) (18,489)
Financing activities    
Dividends paid (4,720) (4,379)
Distributions to noncontrolling interests (380) (389)
Proceeds from exercise of stock options 407
Proceeds from sale of member interests in CS Pharma Holdings, LLC 1,250
Repurchases of Class B common stock (23) (23)
Net cash used in financing activities (5,123) (3,134)
Effect of exchange rate changes on cash and cash equivalents (173) (1,476)
Net decrease in cash and cash equivalents (37,248) (17,609)
Cash and cash equivalents at beginning of period, including $5,716 held for sale at July 31, 2017 96,060 109,537
Cash and cash equivalents at end of period, including $6,057 held for sale at October 31, 2017 58,812 91,928
Supplemental schedule of non-cash financing activities    
Reclassification of liability for member interests in CS Pharma Holdings, LLC $ 8,750